CN113599395A - Pharmaceutical composition for treating cancer containing NK cells - Google Patents
Pharmaceutical composition for treating cancer containing NK cells Download PDFInfo
- Publication number
- CN113599395A CN113599395A CN202111105925.9A CN202111105925A CN113599395A CN 113599395 A CN113599395 A CN 113599395A CN 202111105925 A CN202111105925 A CN 202111105925A CN 113599395 A CN113599395 A CN 113599395A
- Authority
- CN
- China
- Prior art keywords
- cells
- cancer
- tnf
- leu
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111105925.9A CN113599395B (en) | 2021-09-22 | 2021-09-22 | Pharmaceutical composition for treating cancer comprising NK cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111105925.9A CN113599395B (en) | 2021-09-22 | 2021-09-22 | Pharmaceutical composition for treating cancer comprising NK cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113599395A true CN113599395A (en) | 2021-11-05 |
CN113599395B CN113599395B (en) | 2022-08-12 |
Family
ID=78310669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111105925.9A Active CN113599395B (en) | 2021-09-22 | 2021-09-22 | Pharmaceutical composition for treating cancer comprising NK cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113599395B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103849599A (en) * | 2014-03-18 | 2014-06-11 | 加思葆(北京)医药科技有限公司 | Culture medium efficiently amplifying autologous NK cells and cultural method |
CN110662834A (en) * | 2017-05-26 | 2020-01-07 | Gc细胞治疗 | Method for culturing natural killer cells using transformed T cells |
CN110831620A (en) * | 2017-05-26 | 2020-02-21 | 埃特彼塞斯公司 | Combination immunotherapy comprising IL-15 superagonists |
CN112105723A (en) * | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | Therapeutic cell systems and methods for treating cancer and infectious diseases |
CN112105632A (en) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | Cytokine fusion proteins |
WO2021097227A1 (en) * | 2019-11-14 | 2021-05-20 | Altor Bioscience, Llc | Il-15 fusion protein enhanced adoptive cell therapeutics |
US20210230548A1 (en) * | 2018-05-03 | 2021-07-29 | Board Of Regents, The University Of Texas System | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
WO2021183675A2 (en) * | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
-
2021
- 2021-09-22 CN CN202111105925.9A patent/CN113599395B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103849599A (en) * | 2014-03-18 | 2014-06-11 | 加思葆(北京)医药科技有限公司 | Culture medium efficiently amplifying autologous NK cells and cultural method |
CN110662834A (en) * | 2017-05-26 | 2020-01-07 | Gc细胞治疗 | Method for culturing natural killer cells using transformed T cells |
CN110831620A (en) * | 2017-05-26 | 2020-02-21 | 埃特彼塞斯公司 | Combination immunotherapy comprising IL-15 superagonists |
CN112105632A (en) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | Cytokine fusion proteins |
CN112105723A (en) * | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | Therapeutic cell systems and methods for treating cancer and infectious diseases |
US20210230548A1 (en) * | 2018-05-03 | 2021-07-29 | Board Of Regents, The University Of Texas System | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
WO2021097227A1 (en) * | 2019-11-14 | 2021-05-20 | Altor Bioscience, Llc | Il-15 fusion protein enhanced adoptive cell therapeutics |
WO2021183675A2 (en) * | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
Non-Patent Citations (6)
Title |
---|
JIWON LEE ET AL: "Tumor necrosis factor-α enhances IL-15-induced natural killer cell differentiation", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
YUAN HU ET AL: "Chimeric antigen receptor(CAR)-transduced natural killer cells in tumor immunotherapy", 《ACTA PHARACOLOGICA SINICA》 * |
汪健等: "IL-2和IL-15诱导扩增的脐带血NK细胞生物学特性研究", 《中国实验血液学杂志》 * |
王晓梦等: "IL-2+IL-15组合培养方案对乳腺癌患者外周血中NK细胞体外扩增的效果", 《中国肿瘤生物治疗杂志》 * |
胡渊 等: "基于自然杀伤细胞的癌症免疫疗法的进展和前景", 《ENGINEERING》 * |
董茜等: "IL-15对人外周血NK细胞内TNF-α表达的促进作用", 《细胞与分子免疫学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113599395B (en) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7300763B2 (en) | CAR expression vectors and CAR-expressing T cells | |
TWI728308B (en) | A chimeric antigen receptor (car) binding to bcma and use thereof | |
EP3114147B1 (en) | Chimeric antigen receptor | |
CN109320615B (en) | Chimeric antigen receptor targeting novel BCMA and uses thereof | |
KR101985271B1 (en) | Mesenchymal stem cell expressing trail and cd, and use thereof | |
CN112204133B (en) | CAR NK cells | |
CN111944062A (en) | Chimeric antigen receptor for recognizing Fc fragment and application thereof | |
CN113583139A (en) | Chimeric receptor and application thereof | |
AU2020232597A1 (en) | Constitutively active chimeric cytokine receptors | |
WO2017071173A1 (en) | Tumor therapeutic agent modified by il-12/cd62l fusion protein and preparation method and use thereof | |
CN110923255A (en) | Chimeric antigen receptor targeting BCMA and CD19 and uses thereof | |
JP2023548957A (en) | New PiggyBac transposon system and its application | |
CN112513276B (en) | Protein heterodimers and uses thereof | |
CN109666074B (en) | Application of chemokine receptor CXCR5 | |
CN116348496A (en) | BCMA chimeric antigen receptor | |
Hege et al. | T-cell gene therapy | |
WO2018103734A1 (en) | Chimeric antigen receptor and use thereof and preparation method therefor | |
JP7207786B2 (en) | Interleukin 21 protein (IL21) mutants and their applications | |
CN111378046B (en) | Immune effector cell conversion receptor | |
IL292004A (en) | Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type i-producing cells, methods and uses thereof | |
CN113599395B (en) | Pharmaceutical composition for treating cancer comprising NK cells | |
CN113786416B (en) | Use of transgenic NK cells in the treatment of cancer | |
CN113906140A (en) | A2/NY-ESO-1 specific T cell receptor and application thereof | |
JP2022501067A (en) | Chimeric antigen receptors targeting BCMA and CD19, and their use | |
CN112538462B (en) | Cell membrane for rapid amplification of NK cells and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220725 Address after: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province Applicant after: ZHENGZHOU REVO GENE INDUSTRY Co.,Ltd. Applicant after: Zhengzhou Bain Biotechnology Co.,Ltd. Applicant after: Henan Yuanchuang life stem cell bank technology Co.,Ltd. Address before: 100000 510, floor 5, building 2, yard 78, Shuangying West Road, Changping District, Beijing Applicant before: Beijing chuangshike Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province Patentee after: Zhengzhou Yuanchuang Gene Technology Co.,Ltd. Patentee after: Zhengzhou Bain Biotechnology Co.,Ltd. Patentee after: Henan Yuanchuang life stem cell bank technology Co.,Ltd. Address before: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province Patentee before: ZHENGZHOU REVO GENE INDUSTRY Co.,Ltd. Patentee before: Zhengzhou Bain Biotechnology Co.,Ltd. Patentee before: Henan Yuanchuang life stem cell bank technology Co.,Ltd. |